01485nas a2200337   4500000000100000008004100001260001300042653001200055653001100067653001600078653001100094653001300105653001200118653003300130653000900163653000900172653001300181653003100194653001200225653000900237653001800246653002500264653001600289100001500305700001200320245003400332300001000366490000700376520075000383022001401133       1983                            d  c1983 Feb10aAnimals10aFemale10aGuinea Pigs10aHumans10aImmunity10aleprosy10aLupus Erythematosus, Discoid10aMale10aMice10aNeuritis10aPhotosensitivity Disorders10aPrurigo10aRats10aSkin Diseases10aStomatitis, Aphthous10aThalidomide1 aHunziker T1 aKrebs A00a[Thalidomide in dermatology].  a66-720 v343 a<p>Based on present publications we review indications of the therapy of dermatoses with thalidomide as well as possible mechanisms of action and side effects of this drug. In reactional states of leprosy the use of thalidomide is established. Further indications are chronic cutaneous lupus erythematosus, prurigo nodularis, and eventually recurrent aphthosis and certain photodermatoses not responding to usual treatment. Therapeutical trials of thalidomide in diseases in which such a treatment is only occasionally or not at all mentioned in the literature will be reported. Concerning the mechanisms of action emphasis is put on a possible immunosuppression by thalidomide. Among the side effects the thalidomide neuropathy is stressed.</p>  a0017-8470